Photo from Katsuaki Maehara/X
Dec 5, 2023, 18:49
Katsuaki Maehara: Stage Ⅳ EGFRm NSCLC – Sequential Treatment Options
Katsuaki Maehara, Director of Medical Education Colleagues, recently shared the following on Twitter:
“Stage Ⅳ EGFRm NSCLC – Sequential Treatment Options
To organize sequential treatment, data are based on PFS.
We exclude acquired resistance to osimertinib (because the treatments differ).
2nd and 3rd line subsequent therapies cannot be fixed as they are determined by the IC of the Physician, patient/family, etc.”
Source: Katsuaki Maehara/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 12:13
Nov 13, 2024, 11:52
Nov 13, 2024, 11:48
Nov 13, 2024, 11:44
Nov 13, 2024, 11:39
Nov 13, 2024, 11:30
Nov 13, 2024, 11:25
Nov 13, 2024, 11:10
Nov 13, 2024, 10:59